Perrigo Company plc Accounts Payable
Perrigo Company plc (PRGO) had Accounts Payable of $400.40 million as of 2026-06-27, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccountsPayableCurrent · last filed 2026-08-05
- 2026-06-27: Accounts Payable, Current $400.40M.
- 2026-03-28: Accounts Payable, Current $434.80M.
- 2025-12-31: Accounts Payable, Current $474.50M.
- 2025-09-27: Accounts Payable, Current $469.70M.
| Period end | Accounts Payable, Current | Accounts Payable, Current as first filed |
|---|---|---|
| 2026-06-27 | $400.40M 10-Q · filed 2026-08-05 | |
| 2026-03-28 | $434.80M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $474.50M 10-Q · filed 2026-08-05 | |
| 2025-09-27 | $469.70M 10-Q · filed 2025-11-05 | |
| 2025-06-28 | $489.00M 10-Q · filed 2025-08-06 | |
| 2025-03-29 | $502.30M 10-Q · filed 2025-05-07 | |
| 2024-12-31 | $495.20M 10-K · filed 2026-02-26 | |
| 2024-09-28 | $458.50M 10-Q · filed 2024-11-06 | |
| 2024-06-29 | $471.50M 10-Q · filed 2024-08-02 | |
| 2024-03-30 | $453.70M 10-Q · filed 2024-05-07 | |
| 2023-12-31 | $477.70M 10-K · filed 2025-02-28 | |
| 2023-09-30 | $433.10M 10-Q · filed 2023-11-07 | |
| 2023-07-01 | $470.50M 10-Q · filed 2023-08-08 | |
| 2023-04-01 | $505.20M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $537.30M 10-K · filed 2024-02-27 | |
| 2022-10-01 | $461.40M 10-Q · filed 2022-11-08 | |
| 2022-07-02 | $490.40M 10-Q · filed 2022-08-09 | |
| 2022-04-02 | $479.60M 10-Q · filed 2022-05-11 | |
| 2021-12-31 | $411.20M 10-K · filed 2023-02-28 | |
| 2021-10-02 | $405.60M 10-Q · filed 2021-11-12 | |
| 2021-07-03 | $402.40M 10-Q · filed 2021-08-11 | |
| 2021-04-03 | $430.30M 10-Q · filed 2021-05-12 | |
| 2020-12-31 | $451.60M 10-K · filed 2022-03-01 | $543.80M 10-K · filed 2021-03-01 |
| 2020-09-26 | $536.40M 10-Q · filed 2020-11-05 | |
| 2020-06-27 | $489.10M 10-Q · filed 2020-08-05 | |
| 2020-03-28 | $555.80M 10-Q · filed 2020-05-05 | |
| 2019-12-31 | $520.20M 10-K · filed 2021-03-01 | |
| 2019-09-28 | $524.90M 10-Q · filed 2019-11-06 | |
| 2019-06-29 | $513.70M 10-Q · filed 2019-08-08 | |
| 2019-03-30 | $549.20M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $474.90M 10-K · filed 2020-02-27 | |
| 2018-09-29 | $503.60M 10-Q · filed 2018-11-08 | |
| 2018-06-30 | $533.40M 10-Q · filed 2018-08-09 | |
| 2018-03-31 | $512.20M 10-Q · filed 2018-05-08 | |
| 2017-12-31 | $450.20M 10-K · filed 2019-02-27 | |
| 2017-09-30 | $477.10M 10-Q · filed 2017-11-09 | |
| 2017-07-01 | $480.80M 10-Q · filed 2017-08-10 | |
| 2017-04-01 | $476.30M 10-Q · filed 2017-05-30 | |
| 2016-12-31 | $471.70M 10-K · filed 2018-03-01 | |
| 2016-10-01 | $502.90M 10-Q/A · filed 2017-05-23 | $507.90M 10-Q · filed 2016-11-10 |
| 2016-07-02 | $509.10M 10-Q/A · filed 2017-05-22 | $514.10M 10-Q · filed 2016-08-10 |
| 2016-04-02 | $557.20M 10-Q/A · filed 2017-05-22 | $559.90M 10-Q · filed 2016-05-16 |
| 2015-12-31 | $555.80M 10-K · filed 2018-03-01 | $554.90M 10-KT · filed 2016-02-25 |
| 2015-09-26 | $541.20M 10-Q · filed 2015-11-02 | |
| 2015-06-27 | $709.30M 10-K · filed 2017-05-22 | $747.50M 10-K · filed 2015-08-13 |
| 2015-03-28 | $323.20M 10-Q · filed 2015-04-29 | |
| 2014-12-27 | $302.70M 10-Q · filed 2015-02-05 | |
| 2014-09-27 | $309.00M 8-K · filed 2014-11-20 | |
| 2014-06-28 | $364.30M 10-K · filed 2017-05-22 | |
| 2014-03-29 | $325.30M 10-Q · filed 2014-05-07 | |
| 2013-12-28 | $306.70M 10-Q · filed 2014-02-06 | |
| 2013-06-29 | $382.00M 10-K · filed 2014-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |